Altered expression of vesicular monoamine transporter 2 in epileptic patients and experimental rats

Synapse

Volumn 67, Issue 7, 2013, Pages 415-426

  Jiang, Guohui ^a   Cao, Qingqing ^a   Li, Jie ^a   Zhang, Yujiao ^a   Liu, Xiaoya ^a   Wang, Zhihua ^a   Guo, Fen ^a   Chen, Yun ^a   Chen, Yalan ^a   Chen, Guojun ^a   Wang, Xuefeng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Monoamine neurotransmitters; Neuronal excitability; Temporal lobe epilepsy; Vesicular monoamine transporter 2

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; MESSENGER RNA; OXCARBAZEPINE; PHENOBARBITAL; PILOCARPINE; TOPIRAMATE; VALPROIC ACID; VESICULAR MONOAMINE TRANSPORTER 2;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GLIA CELL; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TEMPORAL LOBE EPILEPSY; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANIMALS; AXONS; CASE-CONTROL STUDIES; CYTOPLASM; EPILEPSY, TEMPORAL LOBE; FEMALE; HIPPOCAMPUS; HUMANS; MALE; NEOCORTEX; NEUROGLIA; PILOCARPINE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; TEMPORAL LOBE; TRANSCRIPTION, GENETIC; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84877927508     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21663     Document Type: Article

References (42)

1. Barnett JH, Xu K, Heron J, Goldman D, Jones PB. 2011. Cognitive effects of genetic variation in monoamine neurotransmitter systems: A population-based study of COMT, MAOA, and 5HTTLPR. Am J Med Genet B Neuropsychiatr Genet 156:158-167.
2. Bercovici E, Cortez MA, Wang X, Snead OC. 2009. Monoamine variability in the chronic model of atypical absence seizures. Epilepsia 50:768-775.
3. Berg DA, Kirkham M, Wang H, Frisen J, Simon A. 2011. Dopamine controls neurogenesis in the adult salamander midbrain in homeostasis and during regeneration of dopamine neurons. Cell Stem Cell 8:426-433.
4. Brandt C, Nozadze M, Heuchert N, Rattka M, Loscher W. 2010. Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. J Neurosci 30:8602-8612.
5. Cifelli P, Grace AA. 2011. Pilocarpine-induced temporal lobe epilepsy in the rat is associated with increased dopamine neuron activity. Int J Neuropsychopharmacol 1-8.
6. Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, Rogler LE, Zavolan M, Tuschl T, Rogler CE. 2008. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 173:856-864.
7. Curia G, Longo D, Biagini G, Jones RS, Avoli M. 2008. The pilocarpine model of temporal lobe epilepsy. J Neurosci Meth 172:143-157.
8. Erickson JD, Eiden LE, Hoffman BJ. 1992. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci USA 89:10993-10997.
9. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. 1996. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 93:5166-5171.
10. Fei H, Grygoruk A, Brooks ES, Chen A, Krantz DE. 2008. Trafficking of vesicular neurotransmitter transporters. Traffic 9:1425-1436.
11. Fleckenstein AE, Volz TJ, Hanson GR. 2009. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 56 (Suppl) 1:133-138.
12. Fukui M, Rodriguiz RM, Zhou J, Jiang SX, Phillips LE, Caron MG, Wetsel WC. 2007. Vmat2 heterozygous mutant mice display a depressive-like phenotype. J Neurosci 27:10520-10529.
13. Grace AA. 2012. Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology 62:1342-1348.
14. Guillot TS, Miller GW. 2009. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol Neurobiol 39:149-170.
15. Han Y, Yin H, Xu Y, Zhu Q, Luo J, Wang X, Chen G. 2012. Increased expression of calponin-3 in epileptic patients and experimental rats. Exp Neurol 233:430-437.
16. Harris PE, Ferrara C, Barba P, Polito T, Freeby M, Maffei A. 2008. VMAT2 gene expression and function as it applies to imaging beta-cell mass. J Mol Med (Berl) 86:5-16.
17. Haut SR, Albin RL. 2008. Dopamine and epilepsy: Hints of complex subcortical roles. Neurology 71:784-785.
18. Hermann B, Seidenberg M, Jones J. 2008. The neurobehavioural comorbidities of epilepsy: Can a natural history be developed? Lancet Neurol 7:151-160.
19. Joels M, Baram TZ. 2009. The neuro-symphony of stress. Nat Rev Neurosci 10:459-466.
20. Kobayashi K, Ikeda Y, Haneda E, Suzuki H. 2008. Chronic fluoxetine bidirectionally modulates potentiating effects of serotonin on the hippocampal mossy fiber synaptic transmission. J Neurosci 28:6272-6280.
21. Li YQ, Xue T, Wang L, Xu ZC, Xi ZQ, Yuan J, Wang XF, Chen YM, Zhang M, Yao L. 2009. Up-regulation of epithelial membrane protein-1 in the temporal neocortex of patients with intractable epilepsy. Neurochem Res 34:1594-1602.
22. Lin Z, Zhao Y, Chung CY, Zhou Y, Xiong N, Glatt CE, Isacson O. 2010. High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life. FASEB J 24:2191-2200.
23. Liu Y, Peter D, Roghani A, Schuldiner S, Prive GG, Eisenberg D, Brecha N, Edwards RH. 1992. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70:539-551.
24. Liu YP, Wilkinson LS, Robbins TW. 2004. Effects of acute and chronic buspirone on impulsive choice and efflux of 5-HT and dopamine in hippocampus, nucleus accumbens and prefrontal cortex. Psychopharmacology (Berl) 173:175-185.
25. Majores M, Schoch S, Lie A, Becker AJ. 2007. Molecular neuropathology of temporal lobe epilepsy: Complementary approaches in animal models and human disease tissue. Epilepsia 48 (Suppl 2):4-12.
26. Narboux-Neme N, Sagne C, Doly S, Diaz SL, Martin CB, Angenard G, Martres MP, Giros B, Hamon M, Lanfumey L, Gaspar P, Mongeau R. 2011. Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences. Neuropsychopharmacology 36:2538-2550.
27. Park JH, Enikolopov G. 2010. Transient elevation of adult hippocampal neurogenesis after dopamine depletion. Exp Neurol 222:267-276.
28. Park KI, Lee SK, Chu K, Jung KH, Bae EK, Kim JS, Lee JJ, Lee SY, Chung CK. 2010. Withdrawal of antiepileptic drugs after neocortical epilepsy surgery. Ann Neurol 67:230-238.
29. Pitkanen A, Kharatishvili I, Karhunen H, Lukasiuk K, Immonen R, Nairismagi J, Grohn O, Nissinen J. 2007. Epileptogenesis in experimental models. Epilepsia 48 (Suppl 2):13-20.
30. Pitkanen A, Lukasiuk K. 2011. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 10:173-186.
31. Racine RJ. 1972. Modification of seizure activity by electrical stimulation. I. After-discharge threshold. Electroencephalogr Clin Neurophysiol 32:269-279.
32. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A. 1994. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 91:11651-11654.
33. Rocha L, Alonso-Vanegas M, Villeda-Hernandez J, Mujica M, Cisneros-Franco JM, Lopez-Gomez M, Zavala-Tecuapetla C, Frias-Soria CL, Segovia-Vila J, Borsodi A. 2012. Dopamine abnormalities in the neocortex of patients with temporal lobe epilepsy. Neurobiol Dis 45:499-507.
34. Sala G, Brighina L, Saracchi E, Fermi S, Riva C, Carrozza V, Pirovano M, Ferrarese C. 2010. Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease. J Neural Transm 117:1093-1098.
35. Schuldiner S, Shirvan A, Linial M. 1995. Vesicular neurotransmitter transporters: from bacteria to humans. Physiol Rev 75:369-392.
36. Smolders I, Clinckers R, Meurs A, De Bundel D, Portelli J, Ebinger G, Michotte Y. 2008. Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action. Neuropharmacology 54:1017-1028.
37. Sukumar D, Rengaswamy M, Chakravarthy VS. 2012. Modeling the contributions of Basal ganglia and Hippocampus to spatial navigation using reinforcement learning. PLoS One 7:e47467.
38. Trindade-Filho EM, de Castro-Neto EF, de ACR, Lima E, Scorza FA, Amado D, Naffah-Mazzacoratti Mda G, Cavalheiro EA. 2008. Serotonin depletion effects on the pilocarpine model of epilepsy. Epilepsy Res 82:194-199.
39. Wang L, Luo J, Fang M, Jiang G, Zhang X, Yu W, Wang X. 2012. A new trick of INPP4A: Decreased expression of INPP4A in patients with temporal lobe epilepsy and pilocarpine-induced rat model. Synapse 66:533-541.
40. Werhahn KJ, Landvogt C, Klimpe S, Buchholz HG, Yakushev I, Siessmeier T, Muller-Forell W, Piel M, Rosch F, Glaser M, Schreckenberger M, Bartenstein P. 2006. Decreased dopamine D2/D3-receptor binding in temporal lobe epilepsy: An [18F]fallypride PET study. Epilepsia 47:1392-1396.
41. Yakushev IY, Dupont E, Buchholz HG, Tillmanns J, Debus F, Cumming P, Heimann A, Fellgiebel A, Luhmann HJ, Landvogt C, Werhahn KJ, Schreckenberger M, Potschka H, Bartenstein P. 2010. In vivo imaging of dopamine receptors in a model of temporal lobe epilepsy. Epilepsia 51:415-422.
42. Zheng G, Dwoskin LP, Crooks PA. 2006. Vesicular monoamine transporter 2: Role as a novel target for drug development. AAPS J 8:E682-E692.